India’s pharmaceutical industry has marked a significant achievement with a 15% increase in exports during the financial year 2024–25. This impressive growth highlights India’s continued leadership in the global supply of affordable, high-quality medicines. The export boost has been largely driven by strong demand for generic medicines, vaccines, and Active Pharmaceutical Ingredients (APIs) in key markets such as the United States, Africa, Latin America, and Southeast Asia.
Government policies like the Production Linked Incentive (PLI) scheme, along with the ongoing Make in India initiative, have provided the much-needed infrastructure support and financial encouragement to domestic manufacturers. These schemes have helped Indian pharma companies expand production capacity, enhance research and development, and meet global quality standards.
India’s reputation as the “Pharmacy of the World” continues to grow, with an increasing number of countries depending on Indian medicines for public health needs. Experts believe this growth trend will continue as Indian pharma strengthens its presence in regulated markets, develops new drug formulations, and invests more in digital healthcare solutions and innovation.
This growth not only benefits the economy but also strengthens India’s global position as a trusted healthcare partner.
